Last updated: 8 February 2023 at 7:39pm EST

Malcolm Lloyd-Smith Net Worth




The estimated Net Worth of Malcolm Lloyd Smith is at least $14.1 Million dollars as of 6 February 2023. Mr. Smith owns over 15,318 units of Neurocrine Biosciences stock worth over $5,142,675 and over the last 10 years he sold NBIX stock worth over $8,985,374. In addition, he makes $0 as Chief Regulatory Officer at Neurocrine Biosciences.

Mr. Smith NBIX stock SEC Form 4 insiders trading

Malcolm has made over 25 trades of the Neurocrine Biosciences stock since 2016, according to the Form 4 filled with the SEC. Most recently he sold 15,318 units of NBIX stock worth $1,572,240 on 6 February 2023.

The largest trade he's ever made was selling 29,984 units of Neurocrine Biosciences stock on 7 February 2020 worth over $3,133,928. On average, Malcolm trades about 7,890 units every 84 days since 2014. As of 6 February 2023 he still owns at least 42,337 units of Neurocrine Biosciences stock.

You can see the complete history of Mr. Smith stock trades at the bottom of the page.





Malcolm Lloyd-Smith biography

Malcolm C. Lloyd-Smith serves as Chief Regulatory Officer of the Company. He was appointed Chief Regulatory Officer in September 2014 and is responsible for regulatory affairs and quality assurance. Prior to joining Neurocrine Biosciences, Mr. Lloyd-Smith served at Cadence Pharmaceuticals, Inc. as Senior Vice President, Regulatory Affairs, Quality and Clinical from August 2012 to September 2014, and previously as Senior Vice President, Regulatory Affairs and Quality Assurance from August 2008. Mr. Lloyd-Smith served as Vice President and Head of Global Regulatory Affairs for Elan Pharmaceuticals, Inc. from September 2003 to August 2008, after having served in the United Kingdom as its Vice President, International Regulatory Affairs from March 2002 to August 2003. Previously, Mr. Lloyd-Smith served in various positions of increasing responsibility with DuPont Pharmaceuticals in Germany, Switzerland, USA and UK. Mr. Lloyd-Smith holds a B.Sc. in Pharmacology from the University of Leeds and a M.Sc. in Pharmacological Biochemistry from Hatfield Polytechnic.



How old is Malcolm Smith?

Malcolm Smith is 64, he's been the Chief Regulatory Officer of Neurocrine Biosciences since 2014. There are 3 older and 21 younger executives at Neurocrine Biosciences. The oldest executive at Neurocrine Biosciences, Inc. is William Rastetter, 72, who is the Independent Chairman of the Board.

What's Malcolm Smith's mailing address?

Malcolm's mailing address filed with the SEC is 12780, El Camino Real, San Diego, San Diego County, California, 92014, United States.

Insiders trading at Neurocrine Biosciences

Over the last 21 years, insiders at Neurocrine Biosciences have traded over $159,913,426 worth of Neurocrine Biosciences stock and bought 103,400 units worth $589,660 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Partners L P/Ilbiotechnolog..., and Richard F Pops. On average, Neurocrine Biosciences executives and independent directors trade stock every 8 days with the average trade being worth of $1,567,813. The most recent stock trade was executed by William H Rastetter on 15 August 2024, trading 14,250 units of NBIX stock currently worth $2,090,333.



What does Neurocrine Biosciences do?

neurocrine biosciences, inc of san diego is a product based biopharmaceutical company focusing on the development and commercialization of innovative pharmaceutical products to treat unmet medical needs. the company's research and development efforts are focused on neurological and endocrine diseases and disorders. our product candidates address some of the largest pharmaceutical markets in the world including endometriosis, irritable bowel syndrome, anxiety, depression, pain, diabetes, insomnia, and other neurological and endocrine related diseases and disorders



What does Neurocrine Biosciences's logo look like?

Neurocrine Biosciences, Inc. logo

Complete history of Mr. Smith stock trades at Neurocrine Biosciences

Date
#
Company
Insider
Trans.
Transaction
Shares Price per share Total value Shares after Source
6 Feb 2023 Malcolm Lloyd Smith
Chief Integration Officer
Sale 15,318 $102.64 $1,572,240
6 Feb 2023
42,337
31 Jan 2023 Malcolm Lloyd Smith
Chief Integration Officer
Sale 1,666 $110.02 $183,293
31 Jan 2023
28,582
12 Aug 2022 Malcolm Lloyd Smith
Chief Integration Officer
Option 29,576 $38.70 $1,144,591
12 Aug 2022
26,931
7 Feb 2022 Malcolm Lloyd Smith
Chief Integration Officer
Sale 3,382 $80.48 $272,183
7 Feb 2022
18,731
27 Jul 2021 Malcolm Lloyd Smith
Chief Integration Officer
Sale 16,709 $93.80 $1,567,304
27 Jul 2021
15,801
10 Feb 2021 Malcolm Lloyd Smith
Chief Integration Officer
Option 1,700 $35.99 $61,183
10 Feb 2021
33,110
5 Feb 2021 Malcolm Lloyd Smith
Chief Integration Officer
Sale 4,126 $116.26 $479,689
5 Feb 2021
32,510
25 Jan 2021 Malcolm Lloyd Smith
Chief Integration Officer
Option 18,670 $34.55 $645,049
25 Jan 2021
29,602
5 Aug 2020 Malcolm Lloyd Smith
Chief Integration Officer
Sale 2,257 $118.86 $268,267
5 Aug 2020
26,971
24 Apr 2020 Malcolm Lloyd Smith
Chief Integration Officer
Sale 1,934 $99.45 $192,336
24 Apr 2020
24,941
7 Feb 2020 Malcolm Lloyd Smith
Chief Integration Officer
Sale 29,984 $104.52 $3,133,928
7 Feb 2020
23,200
5 Feb 2020 Malcolm Lloyd Smith
Chief Integration Officer
Sale 3,438 $102.38 $351,982
5 Feb 2020
22,287
14 Oct 2019 Malcolm Lloyd Smith
Chief Integration Officer
Option 9,956 $15.45 $153,820
14 Oct 2019
29,569
6 Feb 2019 Malcolm Lloyd Smith
Chief Integration Officer
Sale 920 $83.58 $76,894
6 Feb 2019
19,238
5 Feb 2019 Malcolm Lloyd Smith
Chief Integration Officer
Sale 1,272 $88.14 $112,114
5 Feb 2019
17,508
6 Nov 2018 Malcolm Lloyd Smith
Chief Integration Officer
Option 9,000 $15.45 $139,050
6 Nov 2018
18,618
5 Feb 2018 Malcolm Lloyd Smith
Chief Integration Officer
Sale 960 $83.19 $79,862
5 Feb 2018
13,982
2 Jan 2018 Malcolm Lloyd Smith
Chief Integration Officer
Option 18,084 $15.45 $279,398
2 Jan 2018
31,101
18 May 2017 Malcolm Lloyd Smith
Chief Integration Officer
Option 9,960 $15.45 $153,882
18 May 2017
17,997
12 Apr 2017 Malcolm Lloyd Smith
Chief Integration Officer
Sale 13,065 $50.42 $658,737
12 Apr 2017
13,017
6 Feb 2017 Malcolm Lloyd Smith
Chief Integration Officer
Sale 843 $43.35 $36,544
6 Feb 2017
1,082
1 Sep 2016 Malcolm Lloyd Smith
Chief Integration Officer
Option 9,000 $15.45 $139,050
1 Sep 2016
9,000
1 Sep 2016 Malcolm Lloyd Smith
Chief Integration Officer
Option 9,000 $15.45 $139,050
1 Sep 2016
9,000
31 May 2016 Malcolm Lloyd Smith
Chief Integration Officer
Option 9,000 $15.45 $139,050
31 May 2016
9,000
31 May 2016 Malcolm Lloyd Smith
Chief Integration Officer
Option 9,000 $15.45 $139,050
31 May 2016
9,000


Neurocrine Biosciences executives and stock owners

Neurocrine Biosciences executives and other stock owners filed with the SEC include: